Coronavirus BREAKTHROUGH: UK secures early access to 90 million doses of COVID-19 vaccine candidates
Potential vaccine Novavax will complete its Phase 3 clinical trial in the UK. If the vaccines are proven to be safe and effective they could be delivered to the UK by the middle of next year.
There are now plans to manufacture the COVID-19 vaccine in the UK and gain access to 60 million doses.
The UK will also co-fund a global clinical trial with the Janssen Pharmaceutical Companies of Johnson & Johnson which will account for the other 30 million doses.
Priority would be given to groups such as health and social care workers and those with conditions that put them at higher risk from the coronavirus.
With the two new deals, the UK has secured access to six vaccine candidates.
MORE TO FOLLOW...